BTIG Upgrades Integra Lifesciences(IART.US) to Hold Rating

BTIG上调英特格拉生命科学(IART.US)至持有评级

moomoo资讯 · 10/07 06:31 · 评级/大行评级

BTIG analyst Ryan Zimmerman upgrades $Integra Lifesciences (IART.US)$ to a hold rating, and maintains the target price at $20.

According to TipRanks data, the analyst has a success rate of 43.8% and a total average return of 1.8% over the past year.

AnalystRecentRatingAutoNews_205141_20241007_81224ed7a9c6bc4b6005da2b0e5bb787bef04281_1728311469677711_mm_en

Furthermore, according to the comprehensive report, the opinions of $Integra Lifesciences (IART.US)$'s main analysts recently are as follows:

Integra LifeSciences has faced persistent operational challenges over the past two years that have been difficult to surmount. A stabilization of the business is necessary to regain investor trust. The company is perceived to persist in establishing hopeful expectations that afford minimal margin for error. Concerns linger that Integra may have set its forecasts for Q4 and the year 2025 at levels that could be overly ambitious.
The valuation of Integra LifeSciences has reached a level where significant downside appears unlikely, according to an analyst. Near-term pressure on the shares might persist due to tax-loss selling as the year concludes, but the stock is beginning to attract the interest of deep value investors.

Note:

TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.

Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.

TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.

BTIG分析师Ryan Zimmerman上调$英特格拉生命科学 (IART.US)$至持有评级，维持目标价20美元。

根据TipRanks数据显示，该分析师近一年总胜率为43.8%，总平均回报率为1.8%。

AnalystRecentRatingAutoNews_205141_20241007_81224ed7a9c6bc4b6005da2b0e5bb787bef04281_1728311469677711_mm_sc

此外，综合报道，$英特格拉生命科学 (IART.US)$近期主要分析师观点如下：

在过去的两年中，Integra LifeSciences一直面临着难以克服的持续运营挑战。为了重新获得投资者的信任，业务的稳定是必要的。人们认为，该公司坚持建立充满希望的预期，将误差余地降至最低。人们仍然担心Integra可能将其对第四季度和2025年的预测设定在过于雄心勃勃的水平。
一位分析师表示，Integra LifeSciences的估值已达到似乎不太可能出现重大下跌的水平。随着年底，由于减税抛售，股票的短期压力可能会持续存在，但该股已开始吸引深度价值投资者的兴趣。

提示:

TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。

TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。

分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。

总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。更多信息

BTIG Upgrades Integra Lifesciences(IART.US) to Hold Rating, Maintains Target Price $20

BTIG Upgrades Integra Lifesciences(IART.US) to Hold Rating

风险及免责提示

声明